期刊文献+

拓扑替康对HL-60细胞增殖的抑制作用

Growth inhibitory effect of TPT on HL-60 cells
下载PDF
导出
摘要 目的:探讨拓扑替康(topotecan,TPT)对人髓系白血病细胞HL-60的增殖抑制作用。方法:采用四甲基偶氮唑盐光吸收法(MTT法)检测不同浓度的TPT(0.05μmol/L、0.10μmol/L、0.15μmol/L、0.20μmol/L及空白对照组)作用HL-60细胞后4h、8h、12h、16h的增殖情况,计算各组细胞的增殖抑制率,并找出TPT作用HL-60细胞的最适时间和最适浓度。倒置显微镜观察细胞生长状态及形态学改变。结果:TPT作用HL-60细胞12h后细胞集落减少,细胞中颗粒及碎片增多。双因素方差分析显示:不同浓度TPT作用不同时间后,对HL-60细胞生长抑制率差异有统计学意义(F时间=312.24,P<0.05;F组别=1110.35,P<0.05)。同一时间点不同浓度的TPT对HL-60细胞的抑制作用随浓度的升高而增强,同一浓度TPT在不同时间点对HL-60细胞的抑制作用随时间的延长而增强,其作用的最适时间和最适浓度分别为12h和0.15μmol/L。结论:拓扑替康能抑制HL-60细胞的增殖,且其抑制作用具有时间和浓度依赖性。 Aim: To investigate the Inhibitory effect of TPT on H L-60 cells proliferation. Methods:With different concentration of topotecon(0.05 μmol/L,0.10 μmol/L,0.15 μmol/L,0.20 μmol/L and control group) ,the HL-60 cells were incubated for 4 h,8 h, 12 h, 16 h, respectively. The inhibitory rate of cell proliferation is assayed by MTT assay. Then, optimal concentration and time was found. At the same time ,growth appearance and morphology of the cells were observed with microscope. Results: The morphology of HL-60 cell changed after the treatment of TPT, such as HL-60 cellcolony decrea- sing, while the cells granule and fragments increased. On the same time spot, the inhibition effect of TPT on HL-60 cells was strengthened with the increase of concentrations. For the same concentration of TPT on different time spot, the inhibition effect of TPT on HL-60 cells was strengthened with the increase of time expansion. The optimal concentration was 0.15 μmol/L of TPT and the optimal time was 12 h among all groups. Conclusion: TPT is able to inhibit the HL-60 cells growth by time- and dose-dependent manners.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2008年第5期950-952,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 拓扑替康 HL-60细胞 增殖抑制 topotecan HL-60 cell catheter cell proliferation two-way analysis of variance
  • 相关文献

参考文献9

二级参考文献34

  • 1高浩荣 沈镇宙.乳腺癌的辅助化疗.乳腺癌[M].上海:上海科技文献出版社,1990.332-338.
  • 2Griffith TS,Kemp TJ.The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.Cancer Chemother Pharmacol,2003;52(3):175~84
  • 3Steinbach D,Sell W,Voigt A et al.BCRP gent expression is asso ciated with a poor response to remission induction therapy in childhood acute myeloid leukemia.Leukemia,2002;16(8):1443~7
  • 4Lee ST,Jang JH,Suh HC.Idarubicin,cytarabine,and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.Am J Hematol,2001;68(4):237~45
  • 5Cohen JD,Schmitt CL Robins HI.Radiosensitization of human T-cell leukmia by thymidine and 41.8 degree C hyperthermia in vitro.Radiat Res,1991;126(3):372~3
  • 6Thompson CB.Apoptosis in the Pathogenesis and Treatment of Disease.Science,1995;267(5203):1456
  • 7Roca J. The mechanisms of DNA topoisomerase[J].Trends Biochem Sci, 1995,20 (2) : 156.
  • 8Ormerod MG, Orr RM , Peacock J H. The role of apoptosis in cell killing by cisplatin:a flow cytometic study[J]. Br J Cancer,1994,69(1) :93.
  • 9Dubrez L,Goldwasser F,Genne P,et al. The role of cycle regulation and apoptosis triggering in determing the sensitivity of leukemic cells to topoisomerase Ⅰ and Ⅱ inhibitors[J]. Leukemia(Baltimore), 1995,9 (6) : 1013.
  • 10Reed JC. Bcl-2 and the regulation of programmed cell death[J]. J Cell Bio1,1994,124(1) : 1.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部